Gleiss Lutz has advised the US listed medical technology manufacturer Teleflex Incorporated on German merger control and foreign investment control aspects of the acquisition of the BIOTRONIK Group’s vascular intervention business.
The acquisition price is approximately EUR 760 million. The acquisition is subject to customary closing conditions, including receipt of certain regulatory approvals.
The acquisition will expand the Teleflex portfolio to include a broad suite of vascular intervention devices such as drug-coated balloons, stents, and ballon catheters.
Teleflex is a global provider of medical technologies in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care.
The BIOTRONIK Group is a Berlin-based global medical technology company group specializing in cardiovascular diseases and chronic pain.
The following Gleiss Lutz team has advised Teleflex on regulatory aspects: Dr. Moritz Holm-Hadulla (partner), Dr. Iris Benedikt-Buckenleib (counsel, both merger control, both Munich), Dr. Jacob von Andreae (partner), Matthias Hahn, Vivien Etzkorn (all foreign investment control, all Düsseldorf).
Forward
